Genome-wide mapping of piggybac transposon integrations in primary human T cells

Journal of Immunotherapy

Volumn 32, Issue 8, 2009, Pages 837-844

  Galvan, Daniel L ^b   Nakazawa, Yozo ^c   Kaja, Aparna ^b   Kettlun, Claudia ^b   Cooper, Laurence J N ^d   Rooney, Cliona M ^c   Wilson, Matthew H ^a,b,c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Genetically modified T cells; Integration sites; T cell immunotherapy; Transposon

Indexed keywords

LENTIVIRUS VECTOR;

ARTICLE; CELL TYPE; CONTROLLED STUDY; CPG ISLAND; GENE MAPPING; GENE SEQUENCE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GENOME; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTO ONCOGENE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPOSON;

CPG ISLANDS; DNA TRANSPOSABLE ELEMENTS; GAMMARETROVIRUS; GENETIC VECTORS; GENOME-WIDE ASSOCIATION STUDY; HELA CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LENTIVIRUS; MUTAGENICITY TESTS; T-LYMPHOCYTES; TRANSCRIPTION INITIATION SITE;

EID: 70349673723     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b2914c     Document Type: Article

References (39)

1. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200:1623-1633.
2. Heslop HE, Ng CYC, Li CF, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modi.ed virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
3. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243-265.
4. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
5. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.
6. Schroder ARW, Shinn P, Chen HM, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110:521-529.
7. Wu XL, Li Y, Crise B, et al. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300:1749-1751.
8. Lewinski MK, Yamashita M, Emerman M, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2006;2:e60.
9. Bushman F, LewinskiM, Ciu. A, et al. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol. 2005;3:848-858.
10. Check E. Gene therapy: a tragic setback. Nature. 2002;420: 116-118.
11. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2- associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-419.
12. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New Engl J Med. 2003;348: 255-256.
13. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401-409.
14. Huang X, Wilber AC, Bao L, et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood. 2006;107:483-491.
15. Huang X, Guo H, Kang J, et al. Sleeping Beauty transposonmediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther. 2008;16:580-589.
16. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961-2971.
17. Yant SR, Wu XL, Huang Y, et al. High-resolution genomewide mapping of transposon integration in mammals. Mol Cell Biol. 2005;25:2085-2094.
18. Cadinanos J, Bradley A. Generation of an inducible and optimized piggyBac transposon system. Nucleic Acids Res. 2007;35:e87.
19. Ding S, Wu X, Li G, et al. Effcient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. 2005;122:473-483.
20. Wang W, Lin C, Lu D, et al. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc Natl Acad Sci USA. 2008;105:9290-9295.
21. Wilson MH, Coates CJ, George AL Jr. PiggyBac transposonmediated gene transfer in human cells. Mol Ther. 2007;15: 139-145.
22. Wu SC, Meir YJ, Coates CJ, et al. PiggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proc Natl Acad Sci USA. 2006;103:15008-15013.
23. Beard BC, Dickerson D, Beebe K, et al. Comparison of HIVderived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther. 2007;15:1356-1365.
24. Hu J, Renaud G, Gomes TJ, et al. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol Ther. 2008;16:1617-1623.
25. Nienhuis AW. Assays to evaluate the genotoxicity of retroviral vectors. Mol Ther. 2006;14:459-460.
26. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006; 13:1031-1049.
27. Berry C, Hannenhalli S, Leipzig J, et al. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol. 2006;2:e157.
28. Fraser MJ, Ciszczon T, Elick T, et al. Precise excision of TTAAspecific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Mol Biol. 1996;5:141-151.
29. Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004;2:e423.
30. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci U S A. 2006;103:1457-1462.
31. Evans-Galea MV, Wielgosz MM, Hanawa H, et al. Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol Ther. 2007;15:801-809.
32. Ivics Z, Katzer A, Stuwe EE, et al. Targeted sleeping beauty transposition in human cells. Mol Ther. 2007;15:1137-1144.
33. Kaminski JM, Huber MR, Summers JB, et al. Design of a nonviral vector for site-selective, e.cient integration into the human genome. FASEB J. 2002;10:1242-1247.
34. Maragathavally KJ, Kaminski JM, Coates CJ. Chimeric Mos1 and piggyBac transposases result in site-directed integration. FASEB J. 2006;20:1880-1882.
35. Wilson MH, Kaminski JM, George AL Jr. Functional zinc finger/sleeping beauty transposase chimeras exhibit attenuated overproduction inhibition. FEBS Lett. 2005;579:6205-6209.
36. Yant SR, Huang Y, Akache B, et al. Site-directed transposon integration in human cells. Nucleic Acids Res. 2007;35:e50.
37. Shi X, Harrison RL, Hollister JR, et al. Construction and characterization of new piggyBac vectors for constitutive or inducible expression of heterologous gene pairs and the identification of a previously unrecognized activator sequence in piggyBac. BMC Biotechnol. 2007;7:5.
38. Dalsgaard T, Moldt B, Sharma N, et al. Shielding of sleeping beauty DNA transposon-delivered transgene cassettes by heterologous insulators in early embryonal cells. Mol Ther. 2009;17:121-130.
39. Garrison BS, Yant SR, Mikkelsen JG, et al. Postintegrative gene silencing within the sleeping beauty transposition system. Mol Cell Biol. 2007;27:8824-8833.